| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publié le 4 Novembre 2009 par serge dans Les infos de l'AMMI
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publié le 3 Novembre 2009 par serge dans maladies mitochondriales
Publié le 2 Novembre 2009 par serge dans Les infos de l'AMMI
Forum d’information sur les maladies rares à Lyon
Vendredi 27 novembre de 9H30 à 17H
37 rue Saint Romain, 69008 Lyon (siège de Merck Serono)
Entrée gratuite, avec inscription obligatoire
PROGRAMME :
Chaque intervention sera suivie de questions de la salle
9h30 Accueil
M. Pierre-Henry Longeray - Président de Merck Serono France
9h40 Ouverture
Pr. Thierry Philip - Vice Président du Conseil régional, délégué à la santé et au sport
M. Lionel Tardy - Député de Haute-Savoie
10h Le Plan national maladies rares
Mme Françoise Antonini - Directrice générale de l’Alliance Maladies Rares et ancien membre Comité national consultatif de labellisation (CNCL) des centres de référence
11h L’organisation de la santé en région
M. Christian Monteil - Président du Conseil général de Haute-Savoie
12h L’organisation des soins spécifique aux maladies rares
Pr Jean-François Cordier - Coordinateur du Centre de référence des maladies
pulmonaires rares, Hôpital Louis Pradel et ancien membre du et ancien membre Comité national consultatif de labellisation (CNCL) des centres de référence
Dr Elisabeth Ollagnon - Neurogénéticienne à la consultation multidisciplinaire pour les maladies neuromusculaires du CHU de la Croix Rousse
13h Déjeuner
14h30 Les maladies rares et le handicap
Mme Nicole Berlière-Merlin - Directrice de la Maison départementale des personnes handicapées (Mdph) du Rhône
M. Eric Rumeau - Directeur de la Maison départementale des personnes handicapées (Mdph) de l’Isère
15h30 Développement, cycle de vie et sécurité des médicaments
M. Frédéric Jouaret – Pharmacien Responsable Merck Serono France, Directeur Qualité & Affaires Pharmaceutiques
16h10 L’action d’une fondation contre les maladies rares : l’exemple de la Fondation Groupama
M. Gabriel de Montfort - Secrétaire général de la fondation Groupama
16h30 L’action des associations de malades : l’exemple de l’Alliance
Maladies Rares
Mme Paulette Morin - Présidente de l’Alliance Maladies Rares
Equipe région Rhône-Alpes de l’Alliance Maladies Rares
17h Clôture
Attention : Programme susceptible de modifications
Contact pour l’inscription:
Tania-Lan JOSEF
Chargée de la régionalisation
Alliance Maladies Rares
Tel. 01.56.53.53.46 / 06 99 91 24 02
tljosef@maladiesrares.org
Publié le 31 Octobre 2009 par serge dans Les infos de l'AMMI

Ce sont des vaccins facultatifs. Seuls les carnets de santé les plus récents consacrent une demi-page aux vaccinations contre les "infections invasives à pneumocoque". Pourtant, ils pourraient s'avérer très utiles dans la lutte contre la grippe A : les vaccins antipneumococciques seraient le meilleur moyen de lutter contre ces complications.
Car la grippe A entraîne fréquemment des infections pulmonaires à pneumocoque, notamment chez les nourrissons ou chez les personnes âgées. Ces infections peuvent déboucher sur une angine, une otite, une pneumonie, une septicémie, une méningite, et même parfois sur une détresse respiratoire aiguë (DRA) nécessitant une hospitalisation.
Des vaccins antipneumococciques existent. Le vaccin "polyosidique 23-valent", dit Pneumo 23, est destiné aux adultes et aux enfants à partir de 5 ans, et est tout particulièrement prescrit aux malades présentant certaines pathologies chroniques ou des antécédents d'infections respiratoires. Le second vaccin, le "conjugué heptavalent", commercialisé sous le nom de "Prevenar", est destiné aux enfants de moins de 2 ans. "Ces deux vaccins font l'objet de recommandations inscrites au calendrier vaccinal", comme l'explique une directive de la Direction générale de la santé (DGS) adressée aux médecins en juillet. "La grippe étant un facteur de risque de surinfection pulmonaire bactérienne, la situation épidémiologique actuelle due au virus grippal A(H1N1) rend encore plus d'actualité l'application des recommandations", précise la DGS.
"Dans l'état actuel des choses, ce n'est pas la grippe A en elle-même, qui est dangereuse, mais ses conséquences. Pour des personnes sans facteur de risque, cette grippe peut simplement se traduire par une forte fièvre et quelques jours au lit", confirme le docteur Florence Maout, ancien chef de clinique des Hôpitaux de Paris. "Mais en revanche, les risques de surinfection sont importants, en particulier chez les enfants, et c'est de cela qu'il faut préserver les malades atteints de la grippe A". Et de rappeler : "Les séquelles des personnes touchées par une méningite à pneumocoque sont gravissimes : 10 % sont atteintes de surdité, 10 % de cécité et 10 % en meurent. Il est indispensable de vacciner les enfants de moins de trois ans avec le Prevenar, mais aussi de les préserver des méningites à haemophilus, prévenues par les vaccins pentavalents et recommandés à partir de deux mois. Quant aux plus grands, c'est de la méningite à méningocoques C qu'il faut les protéger". Des gestes simples pour que la grippe A ne soit qu'un mauvais souvenir.
Par Louise Cuneo
Publié le 25/09/2009 à 16:56 - Modifié le 28/09/2009 à 14:06 Le Point.fr
Publié le 27 Octobre 2009 par serge dans maladies mitochondriales

Publié le 23 Octobre 2009 par serge dans maladies mitochondriales
Publié le 21 Octobre 2009 par serge dans Les infos de l'AMMI
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publié le 20 Octobre 2009 par serge dans maladies mitochondriales
| The H1N1 virus, also called "the swine flu" typically causes fever, cold symptoms (cough, sore throat, runny or stuffy nose), body aches, loss of appetite, and headache. As with any fever, chills may be present. Fatigue is part of most flu illnesses. Vomiting and diarrhea are reported in some and there are now cases where people have respiratory symptoms without a fever. These symptoms range from mild to severe. There are some people that get sick, but never are sick enough to think about seeing a doctor, whereas others with the same virus will die as a result of their infection. At this point it is not possible to know if the infection will spread to epidemic proportions, or if the virus, which now seems as "bad" as most influenza viruses but no worse, will shift to a strain that will cause more or less severe disease. If you think anyone in the family may have the H1N1 virus, we advise that you seek out immediate medical attention. As part of general medical practice, both fever and dehydration should be treated with standard medical management. Sometimes bedrest, ibuprofen or acetaminophen and fluids are what will be recommended. Use of antiviral medication is given for more severe cases (which are believed to be safe in those with a mitochondrial disorder). For those people that have shown to be susceptible to regression after dehydration, the use of IV hydration and appropriate IV rehydration therapies is reasonable. Aspirin should be avoided. Immunization for the H1N1 is now available. The immunization comes as a live attenuated product delivered by spraying it into the nose and as a killed form, which is delivered by injection. The nasal form (live attenuated vaccine) is not recommended for people with chronic health problems, but can be used in people 2-49 years of age that are healthy (such as healthy family members). The inactivated (dead virus) vaccine contains the preservative thimerosal, which was investigated because of the concern it was linked for causing autism. However, in 2004 the experts at the Institute of Medicine concluded there was no evidence of this and further research has indicated there is no health risk or link to autism. It is this inactivated (dead virus) vaccine that is being recommended for those with health problems, which would include mitochondrial disease. It is important to know that it takes several weeks after the immunization is given for the body to build up immunity against the virus. The Center for Disease Control’s Advisory Committee on Immunization Practices has recommended that certain groups receive the 2009 H1N1 vaccine when it first becomes available. These target groups include pregnant women, people who live with or care for children younger than 6 months of age, healthcare personnel, persons between the ages of 6 months and 24 years old,
and people ages of 25 through 64 years of age who are at higher risk for 2009 H1N1 because of chronic health disorders or compromised immune systems. The government is not recommending the immunization for those less than six months of age. For those under 9 years of age the recommendation is two doses of the vaccine separated by four weeks. The group of healthy people between 25-64 years of age are not in the recommended category for immunization because they are less likely to have a bad outcome if they get an H1N1 influenza viral infection. It is reasonable to believe that an H1N1 infection, or any influenza infection in a child with a mitochondrial disease will be worse than that of an otherwise healthy person. The presence of a fever, reduced food intake, risk of dehydration in addition other parts of the body’s cytokine response to the flu will result in a higher risk of injury and subsequent mitochondrial dysfunction that would likely occur in a healthy person. As with any influenza, a certain percentage of infected people will die. Historically this has been the elderly and those that are already ill. The concern among doctors who care for children and adults with mitochondrial disease is that because of the frail state, parents (or affected adults) will choose not to get immunized for fear that the vaccine will make them sick. Understanding the possible risks and the possible benefits should help alleviate this fear. The vaccine given for the 1976 swine flu (a different strain -- so if you were immunized in 1976 it does not help this year) was possibly causally linked to Guillain-Barré syndrome (GBS) in a small minority --- 450 cases for the 45 million people that got the shot, or about 1 in 100,000. This is a paralyzing disorder that is now treatable (and most people that got this disorder did recover). However in 1976 there were no therapies and 30-40 of those 450 people died. It has never been proven that the vaccine caused the increase in GBS. I have spoken with senior scientists that are convinced there was a link and those that truly believe there was no link. Even after more than 30 years this has not been resolved in the scientific community. In the studies of vaccines that followed the 1976 vaccine, no clear answer has emerged and the number the government decided upon is that the risk is on the order of one in one million. Because of this situation it is recommended that people that have ever had GBS in the past do not get the vaccine. This one in one million risk (or one in 100,000 if you chose that number) needs to be considered along side of the risk of death and disability caused by the flu itself. There have been 10-11 deaths in children this week alone from the swine flu, with 86 confirmed pediatric deaths since the swine flu began being tracked in April 2009. Two-thirds of the hospitalizations in children have been in those with underlying medical problems. This vaccine has been tested in children and adults using standard methods. There is no evidence that this vaccine will result in any more adverse reactions than other influenza vaccines. There are no special concerns about this vaccine in particular that are worrisome. Waiting to see if the H1N1 virus will cause an epidemic before making a decision about getting the vaccine (or your child) is the wrong strategy. By the time we know if this is an epidemic, given the month or so it takes to achieve immunity, it will be too late. It is easy to find information on the web that will cause you (or me) to question
vaccine safety but when you read past the questions of concern, there are no clear data to support the concern. There is no way to prevent getting the flu. Of course common sense and strict hand washing are important, but unless you live by yourself and never have contact with another person, you will be exposed to people, and the 100 people every person came into contact with that day. It is simply not possible to make the blanket recommendation that "all children and adults with mitochondrial disease get the H1N1 immunization." That is a decision between you and your doctor. In the last several months almost all of my patients (and their families) have asked me if I recommend the vaccine and I have said to all of them so far "I recommend the H1N1 and the regular flu vaccine in your situation." In addition I have not told a patient they should not receive the vaccine. I am not sure what I will say with the next patient, but to date all have had my recommendation to get the vaccine. In summary, any influenza poses more of a health risk to a person with mitochondrial disease than to an otherwise healthy person. There is no evidence that the H1N1 vaccine poses a risk of injury above and beyond other influenza vaccines (which I have been recommending to my patients for years). If there is an influenza epidemic caused by the H1N1 virus (or other virus that is covered by the regular seasonal flu vaccine) several months from now, getting the vaccine in the middle of the epidemic will likely not be very helpful. It is everyone’s hope there is no epidemic. But if there is an epidemic, those having received vaccination will have the necessary protection. There is a lot of good information in the web, which can be found by going to your search engine and typing "H1N1 Virus Vaccine". The CDC.GOV website can give you up-to-date information about the influenza situation and immunizations. On a personal note, the vaccine just rolled into Cleveland today. My wife just got her H1N1 vaccine when she went into work this evening, I will get mine hopefully when I return to work and we are awaiting instructions from the pediatrician so I can get all my children immunized against the swine flu ASAP (they all have gotten immunized against the seasonal flu). Bruce H. Cohen, MD |
Publié le 15 Octobre 2009 par serge dans maladies mitochondriales
La délégation Franche Comté de l’Alliance organise le mardi 17 novembre de 9h30 à 17h une journée de tables rondes, de témoignages et de débats sur le thème « les centres de compétences maladies rares du CHU de Besançon ».
Programme :
Entrée gratuite, inscription obligatoire.
Possibilité de repas sur place contre une participation de 5 euros
Modération : Sylvie Debras
9h30 Accueil
10h Ouverture
. ARH Franche-Comté
10h20 1ère table ronde
. Pr Magy-Bertrand - Centre de compétence des maladies systémiques et autoimmunes rares de l'adulte
. Dr M.-A. Bertrand - Consultation du Centre de Référence des syndromes d'Evans, des anémies hémolytiques, et des cytopénies autoimmunes sévères
. Consultation du Centre de Référence des maladies héréditaires du métabolisme du CHU de Nancy
11h15 2ème table ronde
. Dr Plouvier - Centre de compétence des maladies autoinflammatoires et arthrites juvéniles
. Pr Deconinck - Centre de compétence des amyloses primitives
. Dr Amsallem - Centre de compétence des maladies inflammatoires du cerveau
. Dr Nobili - Centre de compétence des maladies rénales rares
12h00 Question de la salle
12h35 Repas
14h00 Les Plans nationaux maladies rares 2005-2008 et 2010-2014
. Mme Ginette Volf - Vice Présidente de l’Alliance Maladies Rares
14h30 : Présentation de MaRaDis (Dossier Médical Partagé, téléconsultations pour les maladies rares)
. Mme Patricia Jendel
15h15 Questions de la salle
15h25 Pause
15h40 Témoignages de malades
. Mme Christelle Nicod - Malade isolé non diagnostiqué
. Mme Christiane Outhier - Syndrome de Hirschsprung
. Mme Céline Sauriat - Syndrome de Moebius
. M. René Poiffaut - Syndrome de Kartageger et dyskinésie Cilliaire Primitive
16h25 Conclusion et présentation des activités locales de l’antenne Franche Comté de l’Alliance
. M. Philippe Grammont - Délégué Franche Comté de l’Alliance Maladies Rares
16h45 Clôture
. M. Christian Magnin-Feysot - Président d’honneur du CISS Franche Comté
Lieu : Centre diocésain, 22 rue Mégevand, Besançon
Contact : Philippe Grammont, Délégué Franche Comté de l’Alliance Maladies Rares
06 73 47 64 58 – philippe.grammont@wanadoo.fr
Pour rappel aussi, la délégation Rhône-Alpes organise pour sa part un forum le vendredi 23 novembre, le programme vous sera communiqué très bientôt.
Très cordialement
___________
Tania-Lan Josef
Chargée de la régionalisation
Alliance Maladies Rares
102 rue Didot - 75014 Paris
Tel : 01 56 53 53 46
Mail : tljosef@maladiesrares.org
http://www.alliance-maladies-rares.org
Publié le 14 Octobre 2009 par serge dans maladies mitochondriales
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||